Goodwin advised SpringWorks Therapeutics, Inc. on the offering. American precision medicine company SpringWorks Therapeutics (Nasdaq: SWTX) has closed a public offering of 10,905,171 shares of its common…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
